UK start-up Tropic Biosciences has raised $10m in an oversubscribed series A funding round led by Pontifax AgTech and Five Seasons Ventures. The company is developing a novel treatment for the rare disease called Duchenne muscular dystrophy that affects around one million people worldwide. Tropic is developing disease-resistant bananas and coffee with little or no caffeine levels using gene-editing technology, including CRISPR. The company aims to sell young plants and licence its proprietary genetics to other growers. Like Loading... The global combined market for bananas and coffee is valued at $50bn.
UK start-up Tropic Biosciences has raised $10m in an oversubscribed series A funding round led by Pontifax AgTech and Five Seasons Ventures. The company is developing a novel treatment for the rare disease called Duchenne muscular dystrophy that affects around one million people worldwide. Tropic is developing disease-resistant bananas and coffee with little or no caffeine levels using gene-editing technology, including CRISPR. The company aims to sell young plants and licence its proprietary genetics to other growers. The global combined market for bananas and coffee is valued at $50bn.